Inspira Technologies OXY B.H.N. Ltd Overview
Pro stress-test →Inspira Technologies is a commercial-stage medical device company developing innovative respiratory support and blood monitoring technologies. The company's flagship product, the INSPIRA ART100 system, has FDA clearance for cardiopulmonary bypass and is advancing toward broader clinical deployment in U.S. hospitals, with a $22.5 million purchase order announced in 2025.
Strategic Profile
Pro stress-test →Inspira is positioned as a breakthrough innovator in acute respiratory care, leveraging proprietary Augmented Respiration Technology (ART) to provide alternatives to traditional mechanical ventilation. The company is pursuing a government-focused commercialization strategy while developing next-generation technologies like VORTX, which achieved 99% gas exchange efficiency in animal testing (April 2025), to expand its addressable market.
Competitive Landscape
Pro stress-test →Inspira competes in the acute respiratory support and extracorporeal oxygenation market alongside established players in cardiopulmonary bypass and ECMO systems. Direct competitors include manufacturers of traditional hollow-fiber oxygenators used in bypass circuits, while indirect competition comes from mechanical ventilation platforms and emerging alternative respiratory technologies. Inspira's proprietary VORTX technology differentiates on trauma reduction and zero-pressure-difference design.
Industry Context
Inspira Technologies OXY B.H.N. Ltd operates in Cardiopulmonary bypass and extracorporeal oxygenation systems.
Key facts
Founded: 2018 · Headquarters: Ra'anana, Israel · Employees: N/A · Revenue: N/A · Market cap: $16.2M